ArticleArchives of gynecology and obstetrics2026
Risk-reducing salpingo-oophorectomy in patients with gBRCA-mutated breast cancer.
Article in Archives of gynecology and obstetrics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeBreast cancer (BC) patients with pathogenic germline BRCA1/2 mutations (gBRCA1/2mut) have a substantially increased risk of ovarian cancer (OC). Risk-reducing bilateral salpingo-oophorectomy (RRSO) remains the only effective preventive strategy. However, data on the utilization and time to RRSO in gBRCAmut BC patients are limited.
methodsThis retrospective study included 148 patients with gBRCA1/2mut BC treated at the Hereditary Breast and Ovarian Cancer Center, University Hospital Erlangen, between 2012 and 2024. Clinical, pathological, treatment-related, and genetic data were collected and analyzed from electronic records. Time to RRSO at date of BC surgery was calculated for all patients, and stratified according guideline recommendations for RRSO, using the Kaplan-Meier method.
resultsIn this cohort of 148 patients with gBRCAmut BC, 60.8% harbored a gBRCA1 and 39.2% a gBRCA2 mutation. BC was diagnosed at the mean age of 47.1 years, 73.6% presenting at UICC stage I-II. 47.9% of patients presented with triple-negative BC, 38.4% of patients with hormone receptor (HR)-positive/human epidermal growth factor receptor 2 (HER2)-negative BC and 8.9% with HER2-positive BC. 101 patients (68.2%) additionally underwent RRSOs. The 12-month RRSO-free probability was 0.58 (95% CI 0.50-0.68) and the 24-month RRSO-free probability 0.39 (95% CI 0.31-0.49). Occult OC was detected in three patients at the time of RRSO during BC follow-up, four patients without RRSO were diagnosed with OC after BC.
conclusionsIn real-world setting, RRSO is a common prevention in gBRCAmut BC follow-up. The majority of patients undergo surgery within the first two years following a BC diagnosis. Survival outcomes among patients with BC have improved substantially in recent years. Consequently, developing OC in gBRCAmut BC individuals still remains a risk. RRSO should therefore continue to be offered and discussed in accordance with current guidelines, even in the context of a BC diagnosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.